Tumor-induced osteomalacia (TIO) is a rare and largely underdiagnosed paraneoplastic
condition. Previous reviews often reported incomplete data on clinical aspects, diagnosis or …

Tumor‐induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by
mesenchymal tumors that secrete fibroblast growth factor 23 (FGF23). Patients present with …

Tumor‐induced osteomalacia (TIO) is an acquired fibroblast growth factor 23 (FGF23)‐
related hypophosphatemic osteomalacia caused by phosphaturic mesenchymal tumors …

Objectives The objective of this study was to assess and compare the performance of 68 Ga-
DOTA-conjugated-somatostatin-receptor-targeting-peptides (68 Ga-DOTA-SST) PET/CT …

Background The purpose of this study is to compare the sensitivity of 68Ga-DOTA-JR11 and
68Ga-DOTA-TATE PET/CT for detecting the responsible tumor of tumor-induced …

Objectives Tumor-induced osteomalacia (TIO) is a rare acquired paraneoplastic disorder
characterized by hypophosphatemia resulting from tumor-secreted fibroblast growth factor …

Somatostatin receptor (SSTR) agonist tracers used in nuclear medicine scans are classically
used for neuroendocrine tumor diagnosis and staging. SSTR are however, expressed more …

Context Tumor-induced osteomalacia (TIO) is one of the most common forms of acquired
fibroblast growth factor 23 (FGF23)-related hypophosphatemia and is usually caused by …

Throughout the world, millions of people suffer from fragilizing osteopathies such as
osteomalacia and osteoporosis. Osteomalacia is a rare disorder, corresponding to …

The combination of radioisotopes and nanomaterials is creating a new library of tracers for
molecular imaging, exploiting the sensitivity of nuclear imaging techniques and the size …